Related Experiment Videos
Calcium entry blockers and cardiovacular failure
Insights
Calcium entry blockers offer benefits for ischemia by relaxing blood vessels and protecting heart cells. These drugs improve blood flow and reduce heart workload, aiding recovery and preventing further damage.
Area of Science:
- Cardiovascular Pharmacology
- Ischemia Research
Background:
- Ischemia, affecting heart and other tissues, presents complex challenges in treatment.
- Calcium entry blockers (CEBs) are recognized for their beneficial effects in managing ischemic conditions.
Purpose of the Study:
- To elucidate the multifaceted mechanisms through which calcium entry blockers exert beneficial effects in treating ischemia.
- To detail the specific actions of CEBs on various cardiovascular components and cellular processes.
Main Methods:
- Review and synthesis of known pharmacological effects of calcium entry blockers.
- Analysis of their impact on vascular smooth muscle, myocardial cells, heart rate, and blood flow.
- Examination of effects on platelet aggregation, red blood cell deformability, and endothelial function.
Main Results:
- CEBs exhibit diverse actions including vasodilation, negative inotropic and chronotropic effects, and inhibition of vasospasm.
- They also reduce myogenic activity, inhibit platelet aggregation, and may improve red blood cell deformability.
- Protection of endothelial integrity and cellular protection from anoxia and calcium overload during reperfusion are key benefits.
Conclusions:
- The beneficial effects of calcium entry blockers in ischemia stem from a combination of direct cellular actions and systemic cardiovascular effects.
- In angina pectoris, CEBs improve myocardial oxygen supply-demand balance, enhance coronary perfusion, and support collateral circulation.
- Available calcium entry blockers differ in their specific potencies across various cardiovascular targets.
Abstract:
The beneficial influence of calcium entry blockers in the treatment of ischemia, both in the heart and in other tissues, can be explained by many effects including 1) relaxation of venous smooth muscle cells, in particular those of the splanchnic veins; 2) a negative inotropic effect on the myocardial cells; 3) negative chronotropic effects on the heart; 4) inhibition of vasospastic episodes in coronary and other large arteries; 5) depression of myogenic activity and responsiveness to vasoconstrictor stimuli in precapillary resistance vessels; 6) inhibition of platelet aggregation; 7) possibly, increases in the deformability of hypoxic red blood cells; 8) protection of endothelial integrity and function; and 9) protection of body cells, in particular myocardial cells, from prolonged exposure to anoxia and from massive entry of Ca2+ during reperfusion. In the case of angina pectoris, the effects on the myocardial cell itself, the decrease in preload and afterload, and the improvement of coronary perfusion combine to allow the patient to perform more work before unbalance is reached between the demands of the myocardial cells and their metabolic supply; the increased work performance favors collateral circulation and withdraws part of the reflex load on the heart that originates from the ischemic myocardium. The calcium entry blockers available vary in their potency to affect the different components of the cardiovascular system.